ADTX News and Press, ADiTx Therapeutics Inc. From 09/13/22

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on Septem...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks this morning is a merger agreement, clinical trial da...

Pharmaceutical medications may have allowed us to beat innumerable diseases and significantly increase our lifetimes, but they are not without risk. One chief complaint about most pharmaceuticals is that while they are often effective at mitigating the diseases they are deployed against, the...

A new study has found that pediatric patients who undergo kidney transplants may have better outcomes if the donated kidney comes from a biologically unrelated and living donor in comparison to a deceased donor. For their research, the scientists reviewed data obtained from the Organ Proc...

A new study from Rutgers University has revealed that antibiotics can be a double-edged sword when used in early childhood. The study found that even though early exposure to antibiotics can be effective against bacterial infections in early childhood, they also kill off “good...

There have been more than 25,000 organ transplants per year in the United States since the mid-2000s. On average, around 95 organ transplants are carried out in the country per day, with someone being added to the national organ transplant waiting list every nine minutes . Kidney transpla...

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effec...

Most kidney transplant patients usually stop taking their immunosuppressive drugs before starting cancer immunotherapy treatment to diminish the chances of their immune systems attacking the transplanted organs. However, a new study has found that combining standard antirejection medication ...

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system  BULLTheir ground-breaking ADi(TM) immune reprogramming platform will be initiall...

Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast , a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode ...